Background: species of the family are well-known plant pathogens and animal and human conditional pathogens. Due to the widespread and continuous use of antimicrobials, multidrug-resistant strains continue to emerge, making clinical treatment difficult; therefore, there is an increasing need to clarify the mechanisms of drug resistance.
Methods: A rabbit anal fecal sample was collected by a swab and the streak plate method was used to isolate single colonies. The standard agar dilution method was used to determine the minimum inhibitory concentrations (MICs) against antimicrobials. The complete genome sequence of the bacterium was obtained using Next-Generation Sequencing platforms. The potential resistance gene was annotated based on the Comprehensive Antibiotic Resistance Database (CARD) and verified by molecular cloning. The β-lactamase PSZ-1 was expressed via the pCold I expression vector and its enzyme kinetic parameters were analyzed. The genetic environment and evolutionary process of the novel resistance gene-related sequences were analyzed by bioinformatic methods.
Results: The isolate X85 showed some degree of resistance to penicillins as well as cephalosporins. A novel AmpC resistance gene, designated in this research, was identified to be encoded in the plasmid (pPEX85) of X85. showed resistance to penicillins and several first-, second-and third-generation cephalosporins as well as aztreonam, but it did not show resistance to the fourth-generation cephalosporins or carbapenems tested. Enzyme kinetic assays revealed that it could hydrolyze amoxicillin, penicillin G, cephalothin, and cefazolin, and its hydrolytic activity could be strongly inhibited by the inhibitor avibactam, which was generally consistent with antimicrobial susceptibility testing results. No hydrolytic activity was observed for third-generation cephalosporins or aztreonam.
Conclusion: In this study, a novel AmpC β-lactamase gene, designated was characterized and it was encoded in the plasmid of the bacterium X85. It shows resistance to penicillins and several cephalosporins. The discovery of novel drug resistance mechanisms can help guide the scientific use of drugs in animal husbandry and clinical practice, effectively avoiding the abuse of antimicrobials and thus preventing the further development and spread of bacterial resistance.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389763 | PMC |
| http://dx.doi.org/10.3389/fmicb.2023.1222703 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Integration of paper-based colorimetric microdevice and magnetic nanoparticles affinity for high-throughput capture of antimicrobial resistance-reversing agent from complex natural products.
Biosens Bioelectron
December 2024
Department of Pharmaceutical Analysis, School of Pharmacy, Key Laboratory of Protection, Development and Utilization of Medicinal Resources in Liupanshan Area, Ministry of Education, Ningxia Medical University, Yinchuan, 750004, China. Electronic address:
Efficient analysis of active ingredient in complex natural products is crucial for drug discovery, but developing a simple method for this is challenging. The discovery of drugs against bacterial resistance is urgent because drug-resistant bacteria produce β-lactamases, which inactivate antibiotics and increase infection risks, particularly the AmpC β-lactamase. Here, an integrated analytical model based on colorimetric sensing and magnetic nanoparticles (MNPs) affinity chromatography was developed for screening AmpC β-lactamase inhibitors.
View Article and Find Full Text PDFGenetic characteristics and diversity of PDC variants of Pseudomonas aeruginosa and its clinical relevance.
Infect Genet Evol
December 2024
Department of Clinical Microbiology, Christian Medical College, Vellore 632004, India. Electronic address:
Article Synopsis
- Pseudomonas aeruginosa is highly resistant to antibiotics due to intrinsic and acquired mechanisms, primarily utilizing Pseudomonas-derived cephalosporinase (PDC) and serine Ambler class C β-lactamases through the AmpC gene system.
- * A study analyzed 111 P. aeruginosa isolates from India, identifying the ESAC allele PDC-447 as the most prevalent variant, particularly among carbapenem-resistant strains, while also noting other significant variants like PDC-398 and PDC-397.
- * Genetic mutations in the PDC enzyme, such as T105A in the H-helix region, were linked to increased antibiotic resistance, emphasizing the complexity of resistance mechanisms and
Genomic characterizations of emerging pathogens identified from sepsis patients in Ethiopian referral hospitals.
Emerg Microbes Infect
December 2025
Department of Medical Biochemistry and Microbiology, Biomedical Centre, Uppsala University, Uppsala, Sweden.
Article Synopsis
- Healthcare in low- and middle-income countries is facing challenges due to the rise of multidrug-resistant bacteria, leading to increased illness and death.
- A study conducted in Ethiopia identified 74 bacterial isolates from sepsis patients across four hospitals, revealing significant antimicrobial resistance and clonal patterns among the bacteria.
- Findings highlight the urgency for enhanced infection control measures and improved use of antibiotics, as well as adopting advanced techniques for bacterial identification to combat these emerging threats.
Coexistence of bla and bla resistance genes with a novel ST type in Enterobacter roggenkampii from a stool sample: A genome sequencing study.
J Glob Antimicrob Resist
December 2024
Center of Reproductive Medicine, Sir Run Shaw Hospital, Zhejiang University School of Medicine, Key Laboratory of Reproductive Dysfunction Management of Zhejiang Province, Hangzhou, China. Electronic address:
Article Synopsis
- * Researchers used various methods, including culturing in specific media and advanced sequencing techniques, to isolate and analyze E. roggenkampii from a fecal sample.
- * The study identified a new sequence type (ST3014) and discovered multiple antibiotic resistance genes in the genome of E. roggenkampii, indicating a pressing need for continued monitoring of drug-resistant bacteria.
Aztreonam-avibactam: The dynamic duo against multidrug-resistant gram-negative pathogens.
Pharmacotherapy
December 2024
Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Antimicrobial resistance poses a significant public health challenge, particularly with the rise of gram-negative hospital-acquired infections resistant to carbapenems. Aztreonam-avibactam (ATM-AVI) is a promising new combination therapy designed to combat multidrug-resistant (MDR) gram-negative bacteria, including those producing metallo-β-lactamases (MBLs). Aztreonam, a monobactam antibiotic, is resistant to hydrolysis by MBLs but can be degraded by other β-lactamases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!